Analystreport

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its price target lowered by analysts at HC Wainwright from $9.50 to $6.00. They now have a "buy" rating on the stock

Corvus Pharmaceuticals, Inc.  (CRVS) 
Last corvus pharmaceuticals, inc. earnings: 4/30 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: corvuspharma.com